Integer announced it has entered into a new development agreement and a new supply agreement with Respicardia, Inc. Under the agreements, Integer will be Respicardia’s development partner and majority supplier of the remede implantable pulse generator (IPG) and related products for seven years, the first 5 ½ years as an exclusive supplier. Respicardia’s remede System is a transvenous neurostimulation device that treats moderate to severe central sleep apnea in adult patients. Central Sleep Apnea (CSA) is a serious breathing disorder that disrupts the normal breathing pattern during sleep and negatively affects quality of life and overall cardiovascular health. CSA results from the brain’s failure to send appropriate signals to the respiratory muscles to stimulate breathing.